4-<2-Isopropylmercapto-aethyl>-morpholin | 90726-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-<2-Isopropylmercapto-aethyl>-morpholin
• 英文别名: 4-(2-isopropylsulfanyl-ethyl)-morpholine；4-(2-Propan-2-ylsulfanylethyl)morpholine
• CAS: 90726-70-8
• 化学式: C₉H₁₉NOS
• 分子量: 189.322
• InChiKey: JMZULFROLJHPDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  37.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吗啉-4-乙基硫醇 、 2-溴丙烷 在 乙醇 、 sodium ethanolate 作用下， 生成 4-<2-Isopropylmercapto-aethyl>-morpholin
  参考文献：
  名称：

  Tsatsas,G. et al., Bulletin de la Societe Chimique de France, 1963, p. 2160 - 2162

  摘要：

  DOI：

文献信息

• Oligonucleotide compositions and methods thereof
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US10450568B2

  公开（公告）日：2019-10-22

  Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.

  除其他外，本公开涉及设计的寡核苷酸、组合物及其方法。在一些实施方案中，所提供的寡核苷酸组合物能改变转录本的剪接。在一些实施方案中，所提供的寡核苷酸组合物具有低毒性。在一些实施方案中，所提供的寡核苷酸组合物提供了改进的蛋白质结合概况。在一些实施方案中，所提供的寡核苷酸组合物具有更好的传递性。在一些实施方案中，所提供的寡核苷酸组合物改善了吸收。在一些实施方案中，本公开提供了使用所提供的寡核苷酸组合物治疗疾病的方法。
• CHIRAL DESIGN
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US20170037399A1

  公开（公告）日：2017-02-09

  The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.
• OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
  申请人：Vargeese Chandra

  公开号：US20180216108A1

  公开（公告）日：2018-08-02

  Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
• [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET PROCÉDÉS ASSOCIÉS
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2017192664A1

  公开（公告）日：2017-11-09

  Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.